The shape of the curve
Weight loss on a GLP-1 is not linear. During titration (the first 16-20 weeks), doses are low and loss is modest. Loss accelerates after reaching the maintenance dose and then slows as the body reaches a new balance. The tool draws that curve for your starting weight using the published trial trajectories: SURMOUNT-1 for tirzepatide 15 mg and STEP 1 for semaglutide 2.4 mg.
Why individual timelines differ
Titration speed (some clinicians go slower than the label to manage nausea), adherence, diet and activity, baseline weight, and diabetes status all shift the curve. The trial trajectories are averages of a population that received lifestyle counseling throughout. Use the tool to understand what a typical course looks like and when to expect a plateau, not as a promise. Our plateau guide covers what to do when the curve flattens.